As RNA turnover seems to be impaired in cancer patients, modified nucleosides have been evaluated as potential tumor markers. Modified nucleosides are mainly formed post-transcriptionally in tRNA, set free during RNA metabolism, and excreted in urine. Especially methylated nucleosides play an important role, as their levels are higher in urine from cancer patients. For structural elucidation of known and unknown nucleosides from urine samples of cancer patients, MALDI-TOF MS and MALDI-PSD were used for the first time. This technique generally ensures high sensitivity, mass resolution, and accuracy. In our analytical approach we prepurified nucleosides from urine by affinity chromatography and subsequently separated them by semipreparative high performance liquid chromatography. The different fractions were collected separately and analyzed by MALDI-TOF MS and PSD-MALDI using a mixture of six low molecular weight calibrants for internal or external calibration. The molecular totals formulas based on a mass accuracy of 10 ppm and below were calculated and a systematic data base search was performed. The inherent problem of the MALDI-technique, the reduced sensitivity for low molecular weight substances caused by matrix suppression effects, was reduced by our technique. We identified several nucleosides in urine, which were previously identified via retention times and UV spectra of standards after HPLC analysis. Eight further nucleosides were observed. This work demonstrates for the first time the potential of MALDI-TOF and PSD-MALDI in combination with semipreparative HPLC for assignment of nucleosides in urine. The particularly high mass accuracy of this mass spectrometric method provides opportunities for identifying unknown compounds.
Schram, K. H. Urinary Nucleosides. Mass Spectrom. Rev. 1998, 17, 131–251.
Speer, J.; Gehrke, C. W.; Kuo, K. C.; Waalkes, T. P.; Borek, E. tRNA Breakdown Products as Markers for Cancer. Cancer 1979, 44, 2120–2123.
Bjoerk, G. R.; Ericson, J. U.; Gustafsson, C. E. D.; Hagervall, T. G.; Joensson, Y. H.; Wikstroem, P. M. Transfer RNA Modification. Annu. Rev. Biochem. 1987, 56, 263–287.
Limbach, P. A.; Crain, P. F.; McCloskey, J. A. Summary: The Modified Nucleosides of RNA. Nucleic Acids Res. 1994, 22, 2183–2196.
Dudley, E.; Lemiere, F.; Van Dongen, W.; Langridge, J. I.; El Sharkawi, S.; Games, D. E.; Esmans, E. L.; Newton, R. P. Analysis of Urinary Nucleosides: III. Identification of 5′-deoxycytidine in Urine of a Patient with Head and Neck Vancer. Rapid Commun. Mass Spectrom. 2003, 17, 1132–1136.
Esteva, F. J.; Hortobagyi, G. N. Prognostic Molecular Markers in Early Breast Cancer. Breast Cancer Res 2004, 6, 109–118.
Braun, S.; Kiechle, M.; Harbeck, N. Breast Carcinoma: Biological Principles, Classification, and Prognostic Factors. Internist 2002, 43, 329–339.
Borek, E.; Baliga, B. S.; Gehrke, C. W.; Kuo, C. W.; Belman, S.; Troll, W.; Waalkes, T. P. High Turnover Rate of Transfer RNA in Tumor Tissue. Cancer Res. 1977, 37, 3362–3366.
Marvel, C. C.; Del Rowe, J.; Bremer, E. G.; Moskal, J. R. Altered RNA Turnover in Carcinogenesis: The Diagnostic Potential of Modified Base Excretion. Mol. Chem. Neuropathol. 1994, 21, 353–368.
Tormey, D. C.; Waalkes, T. P.; Gehrke, C. W. Biological Markers in Breast Carcinoma—Clinical Correlations with Pseudouridine, N2,N2-Dimethylguanosine, and 1-Methylinosine. J. Surg. Oncol. 1980, 14, 267–273.
Itoh, K.; Konno, T.; Sasaki, T.; Ishiwata, S.; Ishida, N.; Misugaki, M. Relationship of Urinary Pseudouridine and 1-Methyladenosine to Activity of Leukemia and Lymphoma. Clin. Chim. Acta 1992, 206, 181–189.
Nakano, K.; Shindo, K.; Yasaka, T.; Yamamoto, H. Reversed-Phase High-Performance Liquid Chromatographic Investigation of Mucosal Nucleosides and Bases and Urinary Modified Nucleosides of Gastrointestinal Cancer Patients. J. Chromatogr. 1985, 343, 21–33.
Waalkes, T. P.; Abeloff, M. D.; Ettinger, D. S.; Woo, K. B.; Gehrke, C. W.; Kuo, K. C.; Borek, E. Modified Ribonucleosides as Biological Markers for Patients with Small Cell Carcinoma of the Lung. Eur. J. Cancer Clin. Oncol. 1982, 18, 1267–1274.
Uziel, M.; Smith, L. H.; Taylor, S. A. Modified Nucleosides in Urine: Selective Removal and Analysis. Clin. Chem. 1976, 22, 1451–1455.
Gehrke, C. W.; Kuo, K. C. Ribonucleoside Analysis by Reversed-Phase High-Performance Liquid Chromatography. J. Chromatogr. A 1989, 471, 3–36.
Liebich, H. M.; Di Stefano, C.; Wixforth, A.; Schmid, H. R. Quantitation of Urinary Nucleosides by High-Performance Liquid Chromatography. J. Chromatogr. A 1997, 763, 193–197.
Cohen, L. H.; Gusev, A. I. Small Molecule Analysis by MALDI Mass Spectrometry. Anal. Bioanal. Chem. 2002, 373, 571–586.
Lidgard, R.; Duncan, M. W. Utility of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Analysis of Low Molecular Weight Compounds. Rapid Commun. Mass Spectrom. 1995, 9, 128–132.
Koomen, J. M.; Russell, D. H. Ultraviolet/Matrix-Assisted Laser Desorption/Ionization Mass Spectrometric Characterization of 2,5-Dihydroxybenzoic Acid-Induced Reductive Hydrogenation of Oligonucleotides on Cytosine Residues. J. Mass Spectrom. 2000, 35, 1025–1034.
Dudley, E.; El Sharkawi, S.; Games, D. E.; Newton, R. P. Analysis of Urinary Nucleosides: I. Optimization of High Performance Liquid Chromatography/Electrospray Mass Spectrometry. Rapid Commun. Mass Spectrom. 2000, 14, 1200–1207.
Crow, F. W.; Tomer, K. B.; Gross, M. L.; McCloskey, J. A.; Bergstrom, D. E. Fast Atom Bombardment Combined with Tandem Mass Spectrometry for the Determination of Nucleosides. Anal. Biochem. 1984, 139, 243–262.
Wilson, M. S.; McCloskey, J. A. Chemical Ionization Mass Spectrometry of Nucleosides: Mechanisms of Ion Formation and Estimations of Proton Affinity. J. Am. Chem. Soc. 1975, 97, 3436–3444.
Xu, G.; Di Stefano, C.; Liebich, H. M.; Zhang, Y.; Lu, P. Reversed-Phase High-Performance Liquid Chromatographic Investigation of Urinary Normal and Modified Nucleosides of Cancer Patients. J. Chromatogr. B Biomed. Sci. Appl. 1999, 732, 307–313.
Dutta, S. P.; Crain, P. F.; McCloskey, J. A.; Chheda, G. B. Isolation and Characterization of 1-b-D-Ribofuranosylpyridin-4-One-3-Carboxamide from Human Urine. Life Sci. 1979, 24, 1381–1388.
Mills, G. C.; Davis, N. J.; Lertratanangkoon, K. Isolation and Identification of 1-Ribosylpyridone Nucleosides from Human Urine. Nucleosides Nucleotides 1989, 8, 415–430.
Chang, M. L.; Johnson, B. C. N-Methyl-4-Pyridone-5-Carboxamide as a Metabolite of Nicotinic Acid in Man and Monkey. J. Biol. Chem. 1961, 236, 2096–2098.
Schlimme, E.; Boos, K. S.; Schwarzenau, E.; Frister, H.; Ott, F. G.; Raezke, K. P.; Wilmers, B. Dual Column HPLC Analysis of Modified Ribonucleosides as Urinary Pathobiochemical Markers in Clinical Research. Nucleosides Nucleotides 1990, 9, 407–410.
Saponara, A. G.; Enger, M. D. Occurrence of N2,N2,7-Trimethylguanosine in Minor RNA Species of a Mammalian Cell Line. Nature 1969, 223, 1365–1366.
Published online April 26, 2005
About this article
Cite this article
Kammerer, B., Frickenschmidt, A., Gleiter, C.H. et al. MALDI-TOF MS analysis of urinary nucleosides. J Am Soc Mass Spectrom 16, 940–947 (2005). https://doi.org/10.1016/j.jasms.2005.02.018
- High Performance Liquid Chromatography
- Post Source Decay
- High Performance Liquid Chromatography Separation